CONMED Corporation (CNMD)
| Market Cap | 1.11B |
| Revenue (ttm) | 1.37B |
| Net Income (ttm) | 47.06M |
| Shares Out | 30.14M |
| EPS (ttm) | 1.51 |
| PE Ratio | 24.36 |
| Forward PE | 8.45 |
| Dividend | $0.40 (1.09%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 405,912 |
| Open | 37.80 |
| Previous Close | 37.87 |
| Day's Range | 36.29 - 38.17 |
| 52-Week Range | 33.21 - 61.08 |
| Beta | 0.99 |
| Analysts | Hold |
| Price Target | 48.00 (+30.47%) |
| Earnings Date | Apr 29, 2026 |
About CNMD
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems an... [Read more]
Financial Performance
In 2025, CONMED's revenue was $1.37 billion, an increase of 5.18% compared to the previous year's $1.31 billion. Earnings were $47.06 million, a decrease of -64.47%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CNMD stock is "Hold." The 12-month stock price target is $48.0, which is an increase of 30.47% from the latest price.
News
CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The ...
CONMED Earnings Call Transcript: Q4 2025
Fourth quarter sales grew 7.9% year-over-year, led by strong orthopedic and international performance, while adjusted EPS rose 6.7%. The company exited its GI product lines to focus on high-growth platforms, improved supply chain, and authorized a $150M share repurchase.
CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $3...
CONMED Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management outlined a focused strategy on high-growth platforms—AirSeal, Buffalo Filter, and BioBrace—while exiting the GI business to optimize the portfolio. 2026 guidance reflects steady revenue and EPS, with share repurchases replacing dividends and ongoing supply chain improvements supporting growth.
CONMED Corporation Announces Chief Financial Officer Transition
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and ord...
CONMED Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Finan...
CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 2026
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter 2025 after the market close on Wednesday, January 28, 2026. T...
CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit...
CONMED Earnings Call Transcript: Q3 2025
Q3 2025 saw 6.7% sales growth and 2.9% higher adjusted EPS, led by General Surgery and Orthopedics. Strategic review is underway, the dividend was suspended in favor of a $150M share repurchase program, and guidance for full-year revenue and EPS was narrowed.
CONMED Corporation Announces Third Quarter 2025 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Sales of $337.9 million in...
CONMED Corporation to Announce Third Quarter 2025 Financial Results on November 5, 2025
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2025 after the market close on Wednesday, November 5, 2025. Th...
CONMED Corporation Adds Kim Kelderman to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Kim Kelderman will be joining its Board of Directors effective September 8, 2025. “My fellow directors and I are deli...
CONMED Corporation Announces Quarterly Cash Dividend
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3,...
CONMED Earnings Call Transcript: Q2 2025
Q2 2025 saw 3.1% sales growth and 17.3% higher adjusted EPS, led by strong general surgery and innovation in key product lines. Guidance for full-year revenue and EPS was raised, with supply chain improvements and legislative tailwinds supporting future growth.
CONMED Corporation Announces Second Quarter 2025 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales of $342.3 million incre...
Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer of Merit Medical Systems, Inc.
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Martha Aronson will be stepping down from the company's Board of Directors to assume the role of President and Chief ...
CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The ...
CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Di...
CONMED Earnings Call Transcript: Q1 2025
Q1 2025 saw 3.8% constant currency sales growth, with strong gains in Foot & Ankle, BioBrace, and AirSeal. Adjusted net income and EPS rose over 19% year-over-year. Full-year guidance was raised for revenue and EPS, with tariff impacts mostly in Q4.
CONMED Corporation Announces First Quarter 2025 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increa...
CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The ...
CONMED Corporation Adds Mark Kaye to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. “My fellow directors and I are extrem...
These Analysts Slash Their Forecasts On Conmed After Q4 Results
CONMED Corporation CNMD posted better-than-expected earnings for its fourth quarter, but issued FY25 earnings and revenue guidance below estimates.
CONMED Earnings Call Transcript: Q4 2024
Q4 and full-year 2024 saw solid sales and margin growth, with adjusted EPS up 21% year-over-year. 2025 guidance projects 4–6% constant currency revenue growth and stable margins, while supply chain and tariff risks remain key uncertainties.
CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $3...